134,194 Shares in BioLife Solutions, Inc. (NASDAQ:BLFS) Bought by Raymond James & Associates

Raymond James & Associates bought a new position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 134,194 shares of the medical equipment provider's stock, valued at approximately $2,876,000. Raymond James & Associates owned about 0.29% of BioLife Solutions at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of BioLife Solutions by 11.5% during the first quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider's stock worth $53,208,000 after purchasing an additional 296,727 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of BioLife Solutions by 1,038.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,401,899 shares of the medical equipment provider's stock worth $39,031,000 after purchasing an additional 2,191,002 shares during the last quarter. William Blair Investment Management LLC raised its holdings in shares of BioLife Solutions by 0.8% in the first quarter. William Blair Investment Management LLC now owns 1,726,712 shares of the medical equipment provider's stock valued at $32,031,000 after acquiring an additional 13,785 shares in the last quarter. Granahan Investment Management LLC raised its holdings in shares of BioLife Solutions by 22.8% in the fourth quarter. Granahan Investment Management LLC now owns 1,292,675 shares of the medical equipment provider's stock valued at $21,006,000 after acquiring an additional 240,001 shares in the last quarter. Finally, Geneva Capital Management LLC raised its holdings in shares of BioLife Solutions by 0.7% in the first quarter. Geneva Capital Management LLC now owns 880,215 shares of the medical equipment provider's stock valued at $16,328,000 after acquiring an additional 5,730 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Sarah Aebersold sold 3,000 shares of the company's stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $21.03, for a total transaction of $63,090.00. Following the transaction, the insider now owns 61,683 shares in the company, valued at $1,297,193.49. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, insider Sarah Aebersold sold 3,000 shares of the company's stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $21.03, for a total transaction of $63,090.00. Following the transaction, the insider now owns 61,683 shares in the company, valued at $1,297,193.49. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CMO Todd Berard sold 10,000 shares of the company's stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $20.18, for a total transaction of $201,800.00. Following the transaction, the chief marketing officer now owns 108,894 shares in the company, valued at approximately $2,197,480.92. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company's stock.

BioLife Solutions Stock Down 0.2 %

BLFS traded down $0.04 on Monday, hitting $25.88. The company had a trading volume of 394,400 shares, compared to its average volume of 390,235. The stock has a fifty day moving average price of $22.99 and a 200-day moving average price of $20.23. BioLife Solutions, Inc. has a 12-month low of $8.92 and a 12-month high of $26.73. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.81 and a current ratio of 2.86. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -18.23 and a beta of 1.85.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.08. BioLife Solutions had a negative return on equity of 10.75% and a negative net margin of 59.88%. The company had revenue of $28.33 million for the quarter, compared to analyst estimates of $23.80 million. Analysts predict that BioLife Solutions, Inc. will post -0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BLFS. TD Cowen lifted their price objective on BioLife Solutions from $20.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, July 17th. StockNews.com upgraded BioLife Solutions to a "sell" rating in a report on Friday, May 10th. Craig Hallum lifted their price objective on BioLife Solutions from $23.00 to $30.00 and gave the company a "buy" rating in a report on Monday, August 12th. Benchmark upgraded BioLife Solutions from a "neutral" rating to a "buy" rating and set a $25.00 price objective for the company in a report on Monday, May 13th. Finally, Northland Securities lifted their price objective on BioLife Solutions from $26.00 to $28.00 and gave the company an "outperform" rating in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $26.20.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.